Medicare Will Cover Flu Antivirals Under CMS Demonstration Project
This article was originally published in The Pink Sheet Daily
Executive Summary
The demo will allow CMS to collect data on how drug coverage affects beneficiaries’ health and costs ahead of the Medicare prescription drug benefit in 2006. Bristol’s Symmetrel, Forest’s Flumadine, Gilead’s Tamiflu and GlaxoSmithKline’s Relenza will be covered.
You may also be interested in...
3.5 Mil. Doses Of Sanofi-Aventis’ Fluzone Still Unused, CDC Says
HHS will wait to distribute GSK’s Fluarix until Fluzone supply is exhausted, Centers for Disease Control & Prevention Director Gerberding says. Some states have begun to relax recommendations so that people who are not in high priority groups can get vaccinated.
HHS Seeks Increase In Sanofi-Aventis’ Fluzone Production
HHS is discussing with Sanofi-Aventis whether the company can boost Fluzone production to alleviate an impending flu vaccine shortage.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.